Advertisement
Organisation › Details
Sofinnova Partners SAS
Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise. Sofinnova Partners is a hands-on company builder across the entire value chain of life sciences investments, from seed to later-stage. The firm actively partners with ambitious entrepreneurs as a lead or cornerstone investor to develop transformative innovations that have the potential to positively impact our collective future. Founded in 1972, Sofinnova Partners is a deeply established venture capital firm in Europe, with 50 years of experience backing over 500 companies and creating market leaders around the globe. Today, Sofinnova Partners has over €2.5 billion under management. *
Start | 1997-08-25 established | |
Group | Sofinnova (Group) | |
Industry | venture capital | |
Industry 2 | LIFE SCIENCES | |
Person | Papiernik, Antoine (Sofinnova Partners 201703 Managing Partner + Chairman joined 1997) | |
Person 2 | Lucquin, Denis (Sofinnova Partners 201509 Managing Partner + Chairman) | |
Region | Paris | |
Country | France | |
Street | 7–11 Boulevard Haussmann | |
City | 75009 Paris | |
Tel | +33-1-7623-4100 | |
Address record changed: 2024-01-05 | ||
Basic data | Employees | B: 11 to 50 (2020-04-22) |
Currency | EUR | |
Annual sales | 2,500,000,000 (funds, managed (2023) 2023-12-13) | |
* Document for »About Section«: Sofinnova Partners. (12/13/23). "Press Release: Sofinnova Partners Launches Biovelocita, the First Pan-European Investment Strategy Dedicated to the Creation and Acceleration of Biotech Startups". Paris. | ||
Record changed: 2024-03-30 |
Advertisement
More documents for Sofinnova (Group)
- [1] Cure51 SAS. (3/20/24). "Press Release: Cure51 Raises a €15 Million Seed Round to Harness the Natural Power of Cancer Survivors to Develop First-in-Class Treatments and Transform Cancer into a Curable Disease". Paris....
- [2] Biotimus SAS. (2/20/24). "Press Release: Ex-Google DeepMind and Owkin Scientists Team up to Create Bioptimus to Build the First Universal AI Foundation Model for Biology"....
- [3] GenSight Biologics S.A.. (2/8/24). "Press Release: GenSight Biologics Announces Completion of a €5 million capital Increase with Sofinnova Partners, Invus, UPMC Enterprises and Heights Capital". Paris....
- [4] Disco Pharmaceuticals GmbH. (1/16/24). "Press Release: Disco Pharmaceuticals Launches as the Surfaceome Company with EUR 20 Million in Seed Financing". Cologne & Zurich....
- [5] Sofinnova Partners. (12/13/23). "Press Release: Sofinnova Partners Launches Biovelocita, the First Pan-European Investment Strategy Dedicated to the Creation and Acceleration of Biotech Startups". Paris....
- [6] Sofinnova Partners. (12/13/23). "Press Release: Sofinnova Partners and Gustave Roussy Forge Strategic Alliance to Boost Oncology Startup Acceleration in France". Paris....
- [7] Sofinnova Partners. (12/5/23). "Press Release: Sofinnova Partners Unveils Sofinnova.AI – a Cutting-edge Artificial Intelligence Platform Set to Transform Its Life Sciences Investment practice". Paris....
- [8] GenSight Biologics S.A.. (11/21/23). "Press Release: GenSight Biologics Announces a Successful Offering for an Amount of approximately €4.7 Million". Paris....
- [9] T-Therapeutics Ltd.. (11/15/23). "Press Release: T-Therapeutics Raises £48 Million Series A for Development of Next Generation TCR Therapeutics to Transform Cancer Treatment". Cambridge....
- [10] Nuage Therapeutics. (6/20/23). "Press Release: Nuage Therapeutics Raises €12M in Seed Financing Led by Sofinnova Partners and Asabys". Barcelona....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Advertisement
» top